Eli Lilly and Company (LLY) — closed signal from March 25, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 23, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$895.00 – $920.00Entry zone — fair-value band
$911.61Published — price the day we called it
$1,021.01Target — the price the thesis aimed for
$1,182.73Peak — highest point inside the window, not a realized return
$1,107.08Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 49 days.
Peak price
$1,182.73
peak on June 8, 2026 — not a realized returnPeak gain
+29.7%
peak, from the publication priceWindow close
$1,107.08
end-of-window price, context onlyDays to target
49
Window
March 25, 2026 – June 23, 2026
The thesis — published March 25, 2026
Predicted growth
+12%
over the measurement windowTarget price
$1,021.01
the price the thesis aimed forEntry zone
$895.00 – $920.00
the fair-value band we waited forPrice at publication
$911.61
published March 25, 2026Confidence
72%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Lilly's core business is strong and recent news about Zepbound access at Kroger plus rising LillyDirect spending support demand for obesity treatments. The stock fell sharply and buying momentum hasn't fully stabilized, so a rebound is plausible in the next 0-3 months but timing is less certain than for steadier large-cap names.
Primary drivers
- Obesity drug sales remain strong and support continued demand
- Kroger access and LillyDirect expand where patients can obtain treatment
- Reliable earnings help limit downside during market stress
- Recent oversold move creates potential for a rebound if buying returns
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.